Marshall Wace LLP Sells 230,676 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Marshall Wace LLP trimmed its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 57.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 167,823 shares of the company's stock after selling 230,676 shares during the period. Marshall Wace LLP's holdings in Elanco Animal Health were worth $2,032,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in Elanco Animal Health during the 3rd quarter valued at approximately $35,000. Tidal Investments LLC increased its holdings in Elanco Animal Health by 25.5% in the 3rd quarter. Tidal Investments LLC now owns 84,578 shares of the company's stock valued at $1,242,000 after acquiring an additional 17,206 shares during the last quarter. Franklin Resources Inc. increased its holdings in Elanco Animal Health by 14.0% in the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company's stock valued at $5,349,000 after acquiring an additional 45,795 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Elanco Animal Health by 76.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company's stock worth $147,747,000 after purchasing an additional 4,361,799 shares in the last quarter. Finally, Everence Capital Management Inc. purchased a new position in shares of Elanco Animal Health during the fourth quarter valued at about $209,000. Institutional investors own 97.48% of the company's stock.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, March 11th. The stock was bought at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.89% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ELAN has been the subject of several research reports. Piper Sandler lowered their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Stifel Nicolaus lowered their price target on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a report on Monday, April 14th. UBS Group decreased their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Morgan Stanley dropped their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Finally, Barclays decreased their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, Elanco Animal Health currently has an average rating of "Hold" and a consensus target price of $14.67.

Elanco Animal Health Trading Up 2.9 %

ELAN stock traded up $0.28 during trading on Friday, hitting $9.75. The company had a trading volume of 668,471 shares, compared to its average volume of 4,928,690. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $18.80. The company has a 50 day simple moving average of $9.90 and a 200-day simple moving average of $11.52. The firm has a market capitalization of $4.84 billion, a P/E ratio of 24.34, a PEG ratio of 2.50 and a beta of 1.44. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period last year, the company earned $0.08 EPS. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.